mainzbiomed.com (MYNZ) - Cash per Share

This cash per share chart demonstrates the financial stability of Mainz Biomed N.V. (MYNZ), where the current parameter equals 0.21. Business growth relies on the commercialization of ColoAlert PCR tests and the expansion of insurance reimbursements. Production and IT analytics have been outsourced to third-party contractors to ensure data accuracy. The company is currently scaling sales in Europe while awaiting long-term FDA approval in the US.
Analytical breakdowns for Mainz Biomed N.V. (MYNZ)

Mainz Biomed N.V. (MYNZ) is currently bringing oncology screening systems to market without stable operating revenues. Under these conditions, cash per share becomes a critical indicator of business survival based on previous investment funds. This metric calculates the share of liquid assets per security, determining the capital's defensive potential against market panic. An excess of non-working cash may signal low efficiency in resource management. The cash per share trend clearly demonstrates the company's margin of safety until it reaches break-even.